Browsing by Author "Gambra, Pilar"

Now showing 1 - 4 of 4
  • No Thumbnail Available
    Item
    Consenso sobre riesgo de complicaciones infecciosas en pacientes usuarios de medicamentos biológicos seleccionados. Parte II: Guía clínica chilena de Prevención de Infecciones Asociadas al Uso de Terapias Biológicas (PREVITEB)
    (2019) Cerón Araya, Inés María; Vizcaya Altamirano, María Cecilia; Gambra, Pilar; Ferres Garrido, Marcela Viviana; Bidart, Teresa; Lépez Quizhpi,Tania Lorena; Acuña, María Paz; Álvarez, Ana María; Zubieta, Marcela; Durán, Luisa; Rabagliati Borie, Ricardo Miguel
    The use of biological therapies has meant a great improvement in the management of several conditions like autoimmune, neoplastic or others diseases. Although its use has implied significant improvements in the prognosis of these diseases, it is not exempt from complications: infectious diseases as one of them. The objective of this consensus was to evaluate, from an infectious viewpoint, the safeness of the most frequently used biological therapies and give recommendations for the prevention of infections in patients treated with these drugs. These recommendations were based on the highest quality evidence available for the selected biologics. The consensus counts of 2 manuscripts. This second part is a guideline that details these recommendations through screening strategies, prophylactic therapies and vaccines indications for bacterial, mycobacterial, viral, fungal and parasitic infections, both for adults and children.
  • Thumbnail Image
    Item
    Consenso sobre riesgo de complicaciones infecciosas en pacientes usuarios de medicamentos biológicos seleccionados. Primera parte
    (2019) Cerón Araya, Inés María; Gambra, Pilar; Vizcaya Altamirano, María Cecilia; Ferrés Garrido, Marcela Viviana; Bidart, Teresa; López Quizhpi, Tania Lorena; Acuña, M. Paz; Álvarez, Ana M.; Zubieta, Marcela; Rabello, Marcela; Iruretagoyena Bruce, Mirentxu Inés; Rabagliati Borie, Ricardo Miguel
    The use of biological therapies has meant a great improvement in the management of several conditions like autoimmune, neoplastic or others diseases. Although its use has implied significant improvements in the prognosis of these diseases, it is not exempt from complications: infectious diseases as one of them. The objective of this consensus was to evaluate, from an infectious viewpoint, the safeness of the most frequently used biological therapies and give recommendations for the prevention of infections in patients treated with these drugs. These recommendations were based on the highest quality evidence available for the selected biologics. The consensus counts of two manuscripts. This first part details the risks of developing infectious complications depending on the type of biological used for a certain pathology. This evaluation included a broad search in MEDLINE and Epistemonikos of systematic reviews and meta-analyzes of controlled clinical trials and case- control examining post-treatment infections with anti-TNF alpha, anti-CD20, anti-CD52, CTLA4-Ig and anti-integrins. The research was complemented by a review of: multicentre cohorts of biological users, the MMWR of the CDC, Atlanta, U.S.A., and national registers and scientific societies in which infectious complications derived from the use of biological therapies were mentioned.
  • No Thumbnail Available
    Item
    Consensus of the Chilean Society of Infectious Diseases for the management of episodes of febrile neutropenia in adults and children with cancer
    (2023) Alvarez, Ana Maria; Morales, Ricardo; Raijmakers, Mariella; Barraza, Marlon; Lafourcade, Monica; Duran, Luisa; Contardo, Veronica; Amador, Roberto; Bidart, Teresa; Santolaya, Maria Elena; Flores, Ivonne; Gambra, Pilar; Gonzalez, Claudio; Lopez, Tania; Rabagliati, Ricardo; Vizcaya, Cecilia; Zubieta, Marcela
    The Committee of Infections in Immunocompromised Patients of the Chilean Society of Infectious Diseases presents an update in the Management of febrile neutropenia in adults and children with cancer. It comes from the significant changes that occurred in recent years in the confrontation of these patients. For which a multidisciplinary task force group developed recommendations in relation to their initial handling, laboratory exams required, the initial empirical antimicrobial treatment and in front of known infectious focus, invasive fungal infections and antimicrobial prophylaxis.
  • No Thumbnail Available
    Item
    Support of the laboratory of microbiology and pathological anatomy in the diagnosis and management of infections in cancer patients and transplantation of hematopoietic stem cell transplant receptors
    (2019) Ferres Garrido, Marcela Viviana; Lafourcade, Monica; Gambra, Pilar; Ceron Araya, Ines Maria; Paya, Ernesto; Oddo Benavides, Carlos David
    The confrontation of the differential and etiological diagnosis of the infectious diseases of cancer patients, including hematopoietic stem cells transplant (HSCT) recipients, must correspond to an informed, timely decision that directly affects medical behavior that determines a better survival and quality of life for patients. The main goal of this work was to contribute to the management of these patients developing a useful tool for the clinician to make these decisions. For that, infections were grouped by compromised systems, differentiating the possible etiological agents in bacteria, viruses, fungi and parasites, highlighting the relevant diagnostic tests, mentioning the recommended techniques together with the optimal sample type for proper processing. In addition, under each group of techniques we added the item "level of requirement" to suggest what, in the opinion of the authors and the existing evidence, must be mandatory to have at local level or can be derivable to another laboratory.